What If the Contraceptive Pill Was Never Developed?

The combined oral contraceptive pill's development traces to a specific, somewhat improbable collaboration formed in the early 1950s. Margaret Sanger, the birth control movement's most prominent American activist, and Katharine McCormick, an heiress and one of the first women to graduate from MIT, who provided the bulk of the project's private funding — reportedly around $2 million of her own money, since federal and most private research funding for contraceptive research was essentially unavailable given the era's restrictive social and legal climate around birth control — recruited biologist Gregory Pincus to lead the scientific research. Pincus partnered with John Rock, a Catholic obstetrician and fertility researcher at Harvard, whose religious standing and clinical credibility helped provide crucial legitimacy and access to clinical trial subjects that the more controversial Pincus and Sanger might have struggled to secure alone.

The resulting drug, based on synthetic progesterone research building on earlier work by chemists including Russell Marker and Carl Djerassi, underwent clinical trials in Puerto Rico beginning in 1956 — chosen partly because Massachusetts law at the time still restricted contraceptive distribution and research — before receiving FDA approval for contraceptive use in 1960, under the brand name Enovid. Within just a few years, the pill became one of the most widely adopted medications in American history, with by some estimates over six million American women using it by the mid-1960s, fundamentally changing how women could plan families, pursue education, and participate in the paid workforce.

This scenario's most plausible divergence isn't that hormonal contraception was scientifically impossible to develop through some other path eventually — the underlying reproductive endocrinology was an active area of legitimate scientific research by the 1950s, meaning some version of an oral contraceptive was likely achievable eventually. The more historically grounded divergence concerns the specific, unusual funding and institutional coalition that made its development happen when it did: imagine Katharine McCormick's substantial private funding unavailable — she was, by most accounts, essentially irreplaceable as a funding source given how few other avenues existed for contraceptive research at the time, given federal and mainstream private funding's near-total unavailability for this specific research area — or Margaret Sanger's decades of movement-building and political connections never assembling the initial research team at all.

Without this specific, privately funded, socially controversial research effort succeeding in the 1950s, mainstream pharmaceutical and academic research institutions — more constrained by the era's restrictive laws (contraception remained illegal for married couples in Connecticut until the Supreme Court's 1965 Griswold v. Connecticut decision, and for unmarried individuals in many states until 1972's Eisenstadt v. Baird) and more risk-averse about the social controversy involved — plausibly wouldn't have prioritized this specific research direction for a considerably longer period.

In the years immediately following a failed or significantly delayed pill development effort, birth control methods available to American and eventually global women through the 1960s remain limited to considerably less reliable and less discreet options: barrier methods like diaphragms and condoms, which require correct and consistent use at the moment of intercourse, and the rhythm method, based on tracking fertility cycles, which the Catholic Church itself endorsed as its only sanctioned method but which carried a substantially higher real-world failure rate than hormonal contraception eventually achieved.

The broader social and legal landscape around contraception access, still genuinely contested through the early 1960s even with the pill's approval, would likely have remained even more restrictive and slower to liberalize without a single, dramatically effective, and increasingly popular medication forcing the issue into mainstream political and legal debate — the pill's own existence and rapid adoption is widely credited by historians with helping accelerate the legal challenges that led to Griswold and Eisenstadt, rather than those legal changes happening independently on their own separate timeline.

For individual women through the 1960s and 70s, the absence of reliable, private, female-controlled contraception means family planning remains considerably harder to manage with precision — the specific ability the pill provided, to reliably prevent pregnancy without requiring a male partner's active cooperation at the moment of intercourse, simply doesn't exist in the same form. This mattered enormously for women's practical ability to time pregnancies around education and career decisions, a connection economists and historians studying the pill's social impact have documented extensively.

Economist Claudia Goldin and others have specifically studied the pill's role in enabling more women to pursue extended professional and graduate education, delaying childbearing with a level of reliability previous methods couldn't match — research associating the pill's availability with measurable increases in women's college enrollment, professional degree attainment, and workforce participation from the 1960s onward. A world without that specific tool available at that specific moment plausibly means those trends develop more slowly, unevenly, and with a persistently higher rate of unplanned pregnancy interrupting educational and career plans that the pill's reliability helped many women avoid.

At the broadest scale, the pill's global spread through the 1960s, 70s, and beyond became one of the most significant factors in declining fertility rates worldwide, particularly across industrialized nations, with substantial downstream effects on population growth projections, workforce composition, and economic planning that governments and international organizations had to account for from the late twentieth century onward. A world without reliable, widely available hormonal contraception plausibly means global fertility rate declines happen more slowly and unevenly, with correspondingly different population growth trajectories than the ones actually observed and planned around from the 1970s onward.

The pill's broader cultural and legal influence — its documented role in accelerating landmark contraception-access legal decisions, its association with broader shifts in sexual and social norms often described collectively as the sexual revolution, and its influence on the development of the broader modern feminist movement's political and economic arguments around bodily autonomy and workforce equality — would also unfold differently and, most historians of the period would likely agree, considerably more slowly, given how directly the pill's practical availability is credited with accelerating debates and legal changes that, without it, would have had to develop around less dramatically effective and less immediately popular contraceptive methods.